ArticleThe pharmacogenomics journal2026
Real-world analysis of genotype-guided treatment for carriers of actionable DPYD and UGT1A1 variants.
Article in The pharmacogenomics journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective, matched, case-control study was conducted to compare rates of severe adverse events (SAE) within the first three treatment cycles in DPYD and UGT1A1 variant carriers who received genotype-guided treatment compared to variant carriers who received standard treatment with fluoropyrimidines (FP) and irinotecan. Subjects were matched by at-risk phenotype, chemotherapy regimen, and age. Sixteen subjects received genotype-guided treatment (12 with FP) and were matched to 75 subjects who received standard treatment. The primary endpoint of SAE attributed to the FP or irinotecan was significantly lower in variant carriers receiving genotype-guided treatment (12.5% vs. 50.7%; OR: 0.15; 95% CI: 0.03-0.68). Treatment modifications were also significantly reduced for genotype-guided treatment (12.5% vs. 54.6%; p < 0.05). Six (37.5%) subjects with genotype-guided treatment received and tolerated dose escalation. This real-world study of genotype-guided treatment in DPYD and UGT1A1 variant carriers provides additional evidence of the clinical benefit of genotype-guided treatment to improve patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.